CRISPR Therapeutics AG
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-68.4M | $-23.2M | $-25.5M | $-7.0M |
| Depreciation & Amortization | $3.0M | $925.0K | $127.0K | $38.0K |
| Depreciation | $3.0M | $900.0K | $100.0K | $0 |
| Amortization | — | — | — | — |
| Stock-Based Compensation | $18.9M | $10.8M | $3.7M | $695.0K |
| Net Cash from Operating Activities | $-70.1M | $-52.9M | $59.4M | $-4.8M |
| Investing Activities | ||||
| Capital Expenditures | $7.8M | $3.0M | $1.2M | — |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-8.3M | $31.9M | — | — |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | — | — | — | — |
| Net Cash from Financing Activities | $2.6M | $183.2M | — | — |
| Net Change in Cash | $-75.8M | $159.6M | $155.0M | $584.0K |
| Free Cash Flow | $-77.9M | $-55.9M | $58.3M | — |